Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 8/2021

17.02.2021 | Review Article

Postoperative health-related quality of life of patients with gynecological malignancy: a meta-analysis

verfasst von: Se-Ge Ma, Xue Deng, Lu Xing, Yan Huang

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

We sought to describe the short-term (1, 3, 6, 12 months) QoL changes after surgery for patients with gynecological malignancies in a meta-analysis.

Methods

We collected studies based on the PICOS (patients, intervention, comparison, outcome, and study design) framework (P: patients with gynecological malignancy; I: surgery; C: presurgery; O: QoL scores; S: randomized controlled trials, case-control studies, or cohort studies) in the Cochrane Library, MEDLINE, EMBASE, Web of Science, EBSCO, and China National Knowledge Infrastructure (CNKI) databases up to June 28, 2020. Then, two reviewers independently performed article screening, data extraction, and study quality evaluation. Stata 15.0 software was utilized for data analysis.

Results

Nine studies with 1476 patients were ultimately included. QoL in global health status improved until 12 months after surgery with a maximum improvement (6.99 [0.31, 13.68], P = 0.04), and QoL in emotional functioning reduced significantly until 12 months after surgery with a maximum reduction (14.87 [10.29, 19.45], P < 0.00001). All of the symptom scales were reduced significantly until 12 months postoperation, indicating quality of life improvement. There was a clinical reduction in QoL but symptom experience (−3.31 [−5.51, −1.12], P=0.003) at six months after surgery compared with baseline (presurgery), with only sexual worry being statistically significant (4.61 [0.95, 8.27], P=0.01).

Conclusions

The recovery time varied among each dimension of the postoperative QoL of patients with gynecological malignancies; only a few functions and symptoms began to improve at 1 month postoperation and more at 12 months postoperation. Therefore, it is vitally important to develop extended care programs targeting the multidimensional aspects of QoL for patients with gynecological malignancies after surgery.
Literatur
1.
Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem[J]. Best Pract Res Clin Obstet Gynaecol 20(2):207–225PubMedCrossRef
2.
Lin KY, Edbrooke L, Granger CL et al (2019) The impact of gynaecological cancer treatment on physical activity levels: a systematic review of observational studies[J]. Braz J Phys Ther 23(2):79–92PubMedCrossRef
3.
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017[J]. CA Cancer J Clin 67(1):7–30PubMedCrossRef
4.
Yeganeh L, Harrison C, Vincent AJ et al (2018) Effects of lifestyle modification on cancer recurrence, overall survival and quality of life in gynaecological cancer survivors: a systematic review and meta-analysis[J]. Maturitas 111:82–89PubMedCrossRef
5.
Shah CA, Beck T, Liao JB et al (2017) Surgical and oncologic outcomes after robotic radical hysterectomy as compared to open radical hysterectomy in the treatment of early cervical cancer[J]. J Gynecol Oncol 28(6):e82PubMedPubMedCentralCrossRef
6.
Sekse R, Dunberger G, Olesen ML et al (2019) Lived experiences and quality of life after gynaecological cancer-an integrative review[J]. J Clin Nurs 28(9-10):1393–1421PubMedPubMedCentralCrossRef
7.
REIS N, BEJI NK, COSKUN A (2010) Quality of life and sexual functioning in gynecological cancer patients: results from quantitative and qualitative data[J]. Eur J Oncol Nurs 14(2):137–146PubMedCrossRef
8.
MARQUIS P, CHASSANY O, ABETZ L (2004) A comprehensive strategy for the interpretation of quality-of-life data based on existing methods[J]. Value Health 7(1):93–104PubMedCrossRef
9.
PENAR-ZADARKO B, BINKOWSKA-BURY M, WOLAN M et al (2013) Longitudinal assessment of quality of life in ovarian cancer patients[J]. Eur J Oncol Nurs 17(3):381–385PubMedCrossRef
10.
Jones GL, Jacques RM, Thompson J et al (2016) The impact of surgery for vulval cancer upon health-related quality of life and pelvic floor outcomes during the first year of treatment: a longitudinal, mixed methods study[J]. Psychooncology 25(6):656–662PubMedCrossRef
11.
Chan YM, Ngan HY, Li BY et al (2001) A longitudinal study on quality of life after gynecologic cancer treatment[J]. Gynecol Oncol 83(1):10–19PubMedCrossRef
12.
Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology[J]. J Natl Cancer Inst 85(5):365–376PubMedCrossRef
13.
Greimel ER, Kuljanic Vlasic K, Waldenstrom A et al (2006) The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24.[J]. Cancer 107(8):1812–1822PubMedCrossRef
14.
Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA 283(15):2008–2012PubMedCrossRef
15.
VISTAD I, FOSSÅ SD, DAHL AA (2006) A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer[J]. Gynecol Oncol 102(3):563–572PubMedCrossRef
16.
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13PubMedPubMedCentralCrossRef
17.
Higgins J P T: Green S(editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.​cochrane-handbook.​org.[J].
18.
NOVACKOVA M, HALASKA MJ, ROBOVA H et al (2015) A prospective study in the evaluation of quality of life after vulvar cancer surgery[J]. Int J Gynecol Cancer 25(1):166–173PubMedCrossRef
19.
MINIG L, VÉLEZ JI, TRIMBLE EL et al (2013) Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis[J]. Support Care Cancer 21(3):715–726PubMedCrossRef
20.
Rezk YA, Hurley KE, Carter J et al (2013) A prospective study of quality of life in patients undergoing pelvic exenteration: interim results[J]. Gynecol Oncol 128(2):191–197PubMedCrossRef
21.
FERRANDINA G, MANTEGNA G, PETRILLO M et al (2012) Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study[J]. Gynecol Oncol 124(3):389–394PubMedCrossRef
22.
NOVACKOVA M, HALASKA MJ, ROBOVA H et al (2012) A prospective study in detection of lower-limb lymphedema and evaluation of quality of life after vulvar cancer surgery[J]. Int J Gynecol Cancer 22(6):1081–1088PubMedCrossRef
23.
BARNAŚ E, SKRĘT-MAGIERŁO J, SKRĘT A et al (2012) The quality of life of women treated for cervical cancer[J]. Eur J Oncol Nurs 16(1):59–63PubMedCrossRef
24.
GREIMEL E, DAGHOFER F, PETRU E (2011) Prospective assessment of quality of life in long-term ovarian cancer survivors[J]. Int J Cancer 128(12):3005–3011PubMedCrossRef
25.
Angeles MA, Mallet E, Rouanet P et al (2020) Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies[J]. Int J Gynecol Cancer 30(2):233–240PubMedCrossRef
26.
Xie BG, Lu WY, Huang YH et al (2015) Quality of life in cervical cancer treated with systematic nerve-sparing and modified radical hysterectomies[J]. J Obstet Gynaecol 35(8):839–843PubMedCrossRef
27.
Tanturovski M, Aluloski I, Jovanovska V et al (2019) Assessment of quality of life after diagnosis and treatment of gynecologic-oncology patients: review of the literature[J]. Int J Gynecol Cancer 29(Supplement 4):A581
28.
Ma X, Fu L, Zhu Y et al (2020) PCN301 quality of life of cancer patients in China: a systematic review[J]. Value Health 23(Supplement 1):S76–S77CrossRef
29.
Sprangers MA, Cull A, Groenvold M et al (1998) The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group[J]. Qual Life Res 7(4):291–300PubMedCrossRef
30.
KUMAR S, LONG J, KEHOE S et al (2019) Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis[J]. Int J Gynecol Cancer 29(8):1285–1291PubMedCrossRef
31.
van Walree I C, Hamaker M E, de Rooij B H, et al. Do age and comorbidity impair recovery during two years after treatment for endometrial cancer?[J]. J Geriatr Oncol, 2020.
32.
Ahmed-Lecheheb D, Joly F (2016) Ovarian cancer survivors’ quality of life: a systematic review[J]. J Cancer Surviv 10(5):789–801PubMedCrossRef
33.
TABANO M, CONDOSTA D, COONS M (2002) Symptoms affecting quality of life in women with gynecologic cancer[J]. Semin Oncol Nurs 18(3):223–230PubMedCrossRef
34.
Maree J E, Holtslander L, Maree J E. The experiences of women living with cervical cancer in Africa: a metasynthesis of qualitative studies[J]. Cancer Nurs, 2020.
35.
Feichtinger M, Rodriguez-Wallberg KA (2016) Fertility preservation in women with cervical, endometrial or ovarian cancers[J]. Gynecol Oncol Res Pract 3(1)
36.
Vitale SG, Rossetti D, Tropea A et al (2017) Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives[J]. Updat Surg 69(1):29–34CrossRef
37.
ZAPARDIEL I, CRUZ M, DIESTRO MD et al (2016) Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers[J]. Hum Reprod Update 22(3):281–305PubMedCrossRef
38.
Vitale SG, La Rosa VL, Rapisarda AMC et al (2018) Fertility preservation in women with gynaecologic cancer: the impact on quality of life and psychological well-being[J]. Human Fertility (Cambridge, England) 21(1):35–38CrossRef
39.
SHIRALI E, YARANDI F, GHAEMI M et al (2020) Quality of life in patients with gynecological cancers: a web-based study[J]. Asian Pac J Cancer Prev 21(7):1969–1975PubMedPubMedCentralCrossRef
40.
PYNNÄ K, VUORELA P, ARONEN P et al (2019) Treatment of gynecological malignancies: long-term follow-up of health-related quality of life and healthcare costs[J]. J Comp Eff Res 8(7):475–486PubMedCrossRef
41.
Wiltink L M, King M, Müller F, et al. A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life[J]. Support Care Cancer, 2020.
42.
Hawighorst-Knapstein S, Fusshoeller C, Franz C et al (2004) The impact of treatment for genital cancer on quality of life and body image--results of a prospective longitudinal 10-year study[J]. Gynecol Oncol 94(2):398–403PubMedCrossRef
43.
Greimel ER, Kuljanic Vlasic K, Waldenstrom A et al (2006) The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module[J]. Cancer 107(8):1812–1822PubMedCrossRef
44.
MEDLEY N, ROBINSON A, BAMBURY I et al (2019) What factors affect quality of life in patients with gynaecologic cancers? a prospective cohort study at the university hospital of the West Indies[J]. Int J Gynecol Cancer 29(Supplement 4):A650
45.
Lajtman E (2019) Quality of life in endometrial cancer survivors: a 10-year experience from a cancer center in Slovakia.[J]. Int J Hematol Oncol / UHOD: Uluslararasi Hematoloji Onkoloji Dergisi 29(4):246–255
46.
Watson CH, Lopez-Acevedo M, Broadwater G et al (2019) A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery.[J]. Gynecol Oncol 153(2):399–404PubMedCrossRef
47.
SUNDAR S, CUMMINS C, KUMAR S et al (2019) Quality of life after surgery of varying surgical complexity in advanced ovarian cancer: Results from the international, prospective, multicenter cohort socqer2 study[J]. Int J Gynecol Cancer 29(Supplement 4):A638–A639
48.
BAFFERT S, ALRAN S, FOURCHOTTE V et al (2016) Laparoscopic hysterectomy after concurrent radiochemotherapy in locally advanced cervical cancer compared to laparotomy: a multi institutional prospective pilot study of cost, surgical outcome and quality of life.[J]. Eur J Surg Oncol 42(3):391–399PubMedCrossRef
49.
SMITS A, LOPES A, DAS N et al (2015) The effect of lifestyle interventions on the quality of life of gynaecological cancer survivors: a systematic review and meta-analysis[J]. Gynecol Oncol 139(3):546–552PubMedCrossRef
50.
MOHER D, LIBERATI A, TETZLAFF J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. BMJ 339(jul21 1):b2535PubMedPubMedCentralCrossRef
Metadaten
Titel
Postoperative health-related quality of life of patients with gynecological malignancy: a meta-analysis
verfasst von
Se-Ge Ma
Xue Deng
Lu Xing
Yan Huang
Publikationsdatum
17.02.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2021
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06053-8

Weitere Artikel der Ausgabe 8/2021

Supportive Care in Cancer 8/2021 Zur Ausgabe

Original Article

Opioid use and misuse in children, adolescents, and young adults with cancer: a systematic review of the literature

Commentary

Successful application of focused extracorporeal shockwave therapy for plantar fasciitis in patients suffering from metastatic breast cancer

Original Article

Defining the clinician’s role in mitigating financial toxicity: an exploratory study

Original Article

Nurse navigators’ telemonitoring for cancer patients with COVID-19: a French case study

Original Article

The power of informal cancer caregivers’ writings: results from a thematic and narrative analysis

Original Article

Supportive care of cancer patients with a self-applied photobiomodulation device: a case series

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise